Share ownership Orthocell Limited

OCC

AU000000OCC6

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 10:40:15 13/02/2026 am IST			5-day change	1st Jan Change
0.9200 ^AUD	-2.13%		+1.10%	-15.21%

02/02	Orthocell Eyes Fiscal 2027 Entry Into UK, European Union Markets	MT
19/01	Orthocell posts quarterly revenue of A$3.2 million	RE

Share class: Orthocell Limited

	Vote	Quantity	Free-Float	Total Float
Stock A	0	3,38,600	0	75.86 %
Stock B	1	20,93,26,818	15,88,00,959 ( 75.86 %)
Stock C	0	13,61,230	0

Major shareholders: Orthocell Limited

Name	Equities	%	Valuation
Paul Anderson 2.72 %	73,78,900	2.72 %	5 M $
Ming Hao Zheng 2.607 %	70,73,975	2.607 %	5 M $
Qi Xiao Zhou 2.21 %	59,96,241	2.21 %	4 M $
Jia Xu 1.764 %	47,85,445	1.764 %	3 M $
Wyllie Group Pty Ltd. 1.701 %	46,14,992	1.701 %	3 M $
Patrick John Mchale 1.585 %	43,00,000	1.585 %	3 M $
University of Western Australia 0.8702 %	23,60,973	0.8702 %	2 M $
John Clifford Philpott 0.7551 %	20,48,677	0.7551 %	1 M $
Christopher Ellison 0.6579 %	17,84,911	0.6579 %	1 M $
Rubino Group Pty Ltd. 0.5836 %	15,83,334	0.5836 %	1 M $
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Individuals	13.61%
Other	2.38%
Institutional	1.7%
Unknown	82.31%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	13.61%
Australia	3.21%
United States	0.87%

Based on 1000 largest holdings

Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is a sterile, resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen scaffold used in peripheral nerve repair. OrthoACI or autologous chondrocyte implantation is used for the treatment of articular cartilage defects in the knee and ankle. OrthoACI uses the patientâ€™s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.

Employees

Sector

Advanced Medical Equipment & Technology

Calendar

03/03 - Q2 2026 Earnings Release (Projected)

More about the company